|
|
Expression of miR-203 of pregnant women with preeclampsia and its correlation with the clinical symptoms and pregnancy outcomes |
1. Nanjing Hospital Affiliated to Nanjing University of Traditional Chinese Medicine, Jiangsu Province, 210003; 2. Chifeng Hospital of Inner Mongolia |
|
|
Abstract To investigate the expression of microRNA-203 (mir-203) of pregnant women with preeclampsia, and to study its correlation with the clinical symptoms and pregnancy outcomes. Methods: 137 pregnant women were analyzed from August 2014 to November 2019, which included 52 pregnant women with preeclampsia in study group and 85 normal pregnant women in control group. The systolic blood pressure (SBP), diastolic blood pressure (DBP), proteinuria level, plasma mir-203 level, and pregnancy outcomes of women were compared between the two groups. The correlation between plasma mir-203 expression level and clinical symptoms and pregnancy outcomes of women with preeclampsia was analyzed. Results: The values of SBP and DBP, and the proteinuria level, the expression level of plasma mir-203 of women in the study group were significant higher than those of women in the control group (P<0.05). The incidences of respiratory distress, intrauterine growth restriction, and mortality of perinatal infant in the study group were significant higher than those in the control group, but the Apgar score and birth weight of newborn in the study group were significant lower (P<0.05). The expression of plasma miR-203 of women with preeclampsia was positively correlated with the values of SBP and DBP, and the proteinuria level, the rates of respiratory distress, intrauterine growth restriction, and perinatal mortality, but was negatively correlated with Apgar score and birth weight (P<0.05). Conclusion: MiR-203 is highly expressed in the plasma of pregnant women with preeclampsia, and it is associated with clinical symptoms and pregnancy outcomes, so which can be used as a biomarker for diagnosing, monitoring, and evaluating the prognosis of preeclampsia.
|
|
|
|
|
|
|
|